Q4 2025 Sanofi SA Earnings Call Transcript
Key Points
- Sanofi SA (SNY) reported a strong performance with 9.9% sales growth for the full year 2025, driven by successful new product launches.
- The company achieved a significant milestone with Altuviiio reaching blockbuster status, generating EUR1.2 billion in sales.
- Dupixent sales reached EUR15.7 billion annually, with continued growth across multiple indications, highlighting its strong market position.
- Sanofi SA (SNY) completed strategic acquisitions, including Vicebio and Dynavax, enhancing its vaccines portfolio and expanding its pipeline.
- The company maintained a strong capital structure with low net debt and a conservative net debt to EBITDA ratio, providing flexibility for future growth opportunities.
- Sanofi SA (SNY) expects a decrease in R&D reimbursement from Regeneron, impacting financials in the coming years.
- The company anticipates a slight decline in vaccine sales in 2026, which could affect overall growth.
- There are concerns about potential confusion in the US pediatric vaccination schedule, which could impact vaccine uptake.
- The company faces challenges in the competitive landscape, particularly in the immunology sector with new entrants.
- Sanofi SA (SNY) needs to manage the upcoming loss of exclusivity for Dupixent, which could impact long-term revenue.
Hello, everyone. This is Thomas Kudsk Larsen from the Sanofi IR team. Welcome to the Q4 and full-year 2025 conference call for investors and analysts. As usual, you can find slides on sanofi.com.
Please turn to slide number 3. Here, we have the usual forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements which are subject to substantial risk and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in our slide presentation. In addition, we refer you to our Form 20-F on file with the US SEC and our French Universal Registration Document for a description of these risk factors.
As usual, we'll be making comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions of euros and for Q4 or full year 2025 unless stated otherwise.
Please turn to slide number 4. First, we have a presentation which is a little longer due to full-year results. Then, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
